Switzerland· 66325001
Benepali
A etanercept product containing etanerceptum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Etanercept is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB01 (etanercept), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 9 of them publish a price we can compare per daily dose
Etanercept · ATC L04AB01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of etanercept costs, country by country.
Normalised to the WHO defined daily dose (7 mg), the median price runs from $0.35 in Finland to $35.22 in Switzerland — a ×100 gap.
- Switzerland: $35.22 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Etanercept · price per daily dose (7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$35.22
- FI Finland$0.35
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- etanerceptum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L04AB01
- ATC class
- Etanercept
- Defined daily dose
- 7 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680663250016Fertspr 4 StkCHF 771.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for etanercept.
Graded by severity as the source publishes them — 287 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etanercept · interactions on record
429 records
- 287 severe
- 135 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Etanercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandBenepaliSamsung Bioepis NL B.V.
- CzechiaBENEPALISamsung Bioepis NL B.V., Delft
- FinlandBenepaliSAMSUNG BIOEPIS NL B.V.
- BelgiumBenepali 25 mgSamsung Bioepis NL
- IrelandBenepali 25 mg solution for injection in pre-filled syringeSamsung Bioepis NL B.V.
- Japanエタネルセプト(遺伝子組換え)ファイザー
- SwedenBenepali 25 mg Injektionsvätska, lösning i förfylld sprutaSamsung Bioepis NL B.V.
- IcelandBenepaliSamsung Bioepis NL B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enbrel, Enbrel For Paediatric Use
- Liechtenstein · Enbrel, Enbrel For Paediatric Use
- Norway · Enbrel, Enbrel For Paediatric Use
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d40ce469-ec30-4c1d-b7e8-8f7b2ed2e42d GET /v1/drugs/d40ce469-ec30-4c1d-b7e8-8f7b2ed2e42d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "etanerceptum 50 mg",
"valid_from": "2019-04-01",
"limitations": "[{\"description\":\"<b>Austausch Referenzpräparat/Biosimilar</b><br>\\nDie Behandlung mit BENEPALI bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Für die Behandlung mit BENEPALI ist keine neue Kostengutsprache nötig, wenn in derselben Indikation bereits eine Kostengutsprache für das Referenzpräparat oder ein anderes Biosimilar besteht.<br>\\n<br>\\n<b>Rheumatoide Arthritis, aktive juvenile chronische Arthritis mit polyartikulärem Verlauf und Psoriasis Arthritis</b><br>\\nBehandlung der aktiven rheumatoiden Arthritis, der aktiven juvenilen chronischen Arthritis mit polyartikulärem Verlauf und Psoriasis Arthritis, wenn die vorausgegangene antirheumatische Standardtherapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Morbus Bechterew (Ankylosierende Spondylitis)</b><br>\\nBehandlung des Morbus Bechterew, wenn die vorausgegangene konventionelle Therapie unzulänglich war.<br>\\n<br>\\n<b>Schwere Plaque Psoriasis</b><br>\\nBehandlung erwachsener Patienten mit schwerer Plaque-Psoriasis, bei denen eine Phototherapie oder eine der folgenden konventionellen systemischen Therapien (Ciclosporin, Methotrexat, Acitretin) keinen therapeutischen Erfolg gezeigt haben. Falls nach 12 Wochen kein therapeutischer Erfolg eingetreten ist, ist die Behandlung abzubrechen. Standarddosierung pro Behandlungszyklus: 1 x 50 mg pro Woche oder 2 x 25 mg pro Woche während 24 Wochen. In Ausnahmefällen kann die Dosierung während 12 Wochen auf maximal 2 x 50 mg pro Woche erhöht werden. Die Verschreibung kann nur durch Fachärzte der Dermatologie oder dermatologische Universitätskliniken/Polikliniken erfolgen.<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-04-01\",\"validTo\":null}]",
"galenic_form": "Inj Lös 50 mg/ml",
"therapeutic_area": null,
"sl_inclusion_date": "2019-04-01",
"self_retention_pct": 10
}See everything about etanercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.